/

TMDX

TransMedics Group, Inc.Open

78.18+0.01 +0.01%USD

NasdaqGM · as of Oct 13, 10:18 ET · 15m delay

Open

78.17

Prev close

78.17

Day range

77.8679.00

52-week range

60.11156.00

Volume

48.45K0.06×

Mkt cap

2.71B

P/E ttm

20.25

Fwd P/E

34.68

EPS ttm

3.86

Div yield

0.00%

Earnings

Aug 4, 2026

From 52w high

−49.89%

Price Chart

Yahoo Finance · delayed

TMDXOct 13, 2026O 78.17H 79.00L 77.86C 78.18+0.01 (+0.01%)Vol 48.45K

SMA 5085.70
SMA 20098.37

1Y change −27.14% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

TMDX TransMedics Group, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −2.62%
1 month: −4.87%
3 months: +4.81%
6 months: −32.42%
Year to date: −35.74%
1 year: −30.02%

Valuation & ownership

Market cap: 2.71B
Enterprise value: 3.11B
P/E (ttm): 20.25
Forward P/E: 34.68
PEG ratio: 0.67
Price / book: 5.23
Price / sales (ttm): 4.06
EV / EBITDA: 26.86
EPS (ttm): 3.86
EPS (forward): 2.25
Beta (5y monthly): 1.93
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 34.68M
Float: 33.51M
Short % of float: 38.40%
Short ratio (days): 11.71
Held by insiders: 3.64%
Held by institutions: 102.90%
Avg volume (3m): 811.32K
50-day average: 85.77
200-day average: 98.62
52-week change: −30.02%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 39.7
vs 50-day SMA: −8.79%
vs 200-day SMA: −20.53%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 4.79%
Realised vol (20d, ann.): 36.4%
From 52-week high: −49.89%
From 52-week low: +30.06%

ANR

Analyst Consensus

11 analysts

Consensus

Buy

1.85 on a 1 (strong buy) – 5 (sell) scale

Mean target

99.82

+27.69% implied

Low 65.00Median 100.00High 125.00

Recommendation trend

Now9 / 4 / 0
1m ago / 4 /

DES

About TransMedics Group, Inc.

Yahoo Finance profile

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Sector: Healthcare
Industry: Medical Devices
Employees: 898
Headquarters: Andover, MA, United States
Website: transmedics.com
Officers: Dr. Waleed H. Hassanein M.D. Founder, President, CEO & Director
Mr. Nicholas Corcoran Senior Vice President of Supply Chain & Operations

SEAS

Seasonality · TMDX

2019–2026 · monthly returns

Strongest month Nov +22.32%Weakest month Oct −14.46%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	10.1	8.4	-31.6	1.4	-33.3	-1.2	15.2	10.9	-1.7	-6.3			−35.7%
2025	8.3	13.0	-11.8	36.8	38.2	5.4	-11.2	-3.4	-2.4	17.2	11.2	-16.9	+95.1%
2024	8.7	-4.9	-9.4	27.3	44.9	10.4	-5.6	18.1	-6.6	-47.8	5.8	-28.1	−21.0%
2023	2.1	27.1	-5.4	4.5	-8.1	15.6	11.0	-29.6	-16.6	-31.5	101.9	4.3	+27.9%
2022	-17.2	16.7	45.5	-22.2	39.2	7.8	28.4	28.9	-19.8	15.5	28.3	-0.2	+222.1%
2021	14.5	57.6	15.6	-30.8	-10.7	29.4	-14.0	14.6	1.3	-17.1	-19.7	-13.1	−3.7%
2020	-7.9	-10.3	-23.1	49.8	-27.0	35.7	0.8	-1.3	-22.7	-13.1	24.1	33.8	+4.7%
2019						6.6	-18.1	0.9	-0.8	-24.5	4.5	1.4	−30.1%

INSD

Insider Activity · TMDX

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

153.1K shares

Sells, 6 months

9.6K shares

Net shares

+143.5K

Net change in insider shares

+12.80%

Date	Insider	Transaction	Shares	Value
Sep 10, 2026	Weill DavidDirector	Purchase at price 81.63 per share.	1.3K	$109.06K
Aug 16, 2026	Tobin James RDirector	Stock Gift at price 0.00 per share.	18K	—
Jul 9, 2026	Corcoran NicholasOfficer	Stock Award(Grant) at price 0.00 per share.	11.7K	—
Jul 9, 2026	Hernandez GerardoChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	17.2K	—
Jul 9, 2026	Hassanein Waleed HChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	49.7K	—
Jun 14, 2026	Gunderson Thomas JamesDirector	Sale at price 75.06 per share.	9.6K	$722.38K
Jun 14, 2026	Gunderson Thomas JamesDirector	Conversion of Exercise of derivative security at price 2.21 per share.	19.3K	$42.62K
May 19, 2026	Kania Edwin M JrDirector	Stock Award(Grant) at price 0.00 per share.	2.9K	—
May 19, 2026	Tobin James RDirector	Stock Award(Grant) at price 0.00 per share.	2.9K	—
May 19, 2026	Raines MerileeDirector	Stock Award(Grant) at price 0.00 per share.	2.9K	—
May 19, 2026	Gunderson Thomas JamesDirector	Stock Award(Grant) at price 0.00 per share.	2.9K	—
May 19, 2026	Lovell StephanieDirector	Stock Award(Grant) at price 0.00 per share.	2.9K	—
May 19, 2026	Basile Edward M.Director	Stock Award(Grant) at price 0.00 per share.	2.9K	—
May 19, 2026	Weill DavidDirector	Stock Award(Grant) at price 0.00 per share.	2.9K	—
May 18, 2026	Forsyth Matthew SGeneral Counsel	Stock Award(Grant) at price 0.00 per share.	15.4K	—
Mar 3, 2026	Hernandez GerardoChief Financial Officer	Sale at price 139.12 - 147.21 per share.	7.6K	$1.12M
Mar 3, 2026	Hernandez GerardoChief Financial Officer	Conversion of Exercise of derivative security at price 69.84 - 77.12 per share.	7.2K	$515.00K
Mar 3, 2026	Lovell StephanieDirector	Sale at price 149.62 per share.	1.2K	$178.50K
Mar 3, 2026	Weill DavidDirector	Sale at price 146.82 per share.	3.6K	$524.29K
Mar 3, 2026	Weill DavidDirector	Conversion of Exercise of derivative security at price 14.20 per share.	3.6K	$50.71K

13F

Investors Holding TMDX

latest 13F filings of 29 followed managers

Investors holding TMDX
Investor	Value	Of portfolio	Shares	Change	Quarter
Oaktree Capital · Howard Marks	$3.4M	0.05%	3.13M	New	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

TMDX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

TMDX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About TransMedics Group, Inc.

Seasonality · TMDX

Insider Activity · TMDX

Congress Trades · TMDX

Investors Holding TMDX

Investors Holding TMDX

Congress Trades · TMDX

Insider Activity · TMDX

Seasonality · TMDX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About TransMedics Group, Inc.

Financial Snapshot

Earnings & Dividends

News